ELUXA 3: A phase III study of olmutinib compared to afatinib in patients with non-small-cell lung cancer.
Phase of Trial: Phase III
Latest Information Update: 17 Jun 2016
At a glance
- Drugs Olmutinib (Primary) ; Afatinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ELUXA 3
- 17 Jun 2016 New trial record
- 02 Jun 2016 According to Boehringer Ingelheim media release, this trial will be initiated in 2016.